Company intelligence / Profile preview

Promore Pharma

Ownership: Private
Development stage: Phase 3

Overview

Promore Pharma was developing therapeutic peptides for wound care, with ensereptide (PXL01) for preventing post-surgical adhesions and dermal scarring, and ropocamptide (LL-37) for treating chronic leg ulcers. However, the company entered into voluntary liquidation in October 2023.

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: Therapeutic peptides
Industry: Biotech

Drug pipeline

1 asset

ensereptide

Beyond the preview

Go deeper on Promore Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promore Pharma.

Explore the full profile